RECOMBINANT (RV-CEA) IN LOW TUMOR BURDEN ADENOCARCINOMA OF THE COLON

重组 (RV-CEA) 治疗低肿瘤负荷结肠腺癌

• 批准号: 3739016
• 负责人: ALBERT F LO BUGLIO
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3739016
• 关键词: adenocarcinoma; cancer risk; chemoprevention; clinical trials; colon neoplasms; drug administration rate /duration; drug screening /evaluation; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; neoplasm /cancer relapse /recurrence; recombinant proteins; vaccinia virus; viral vaccines

This is a phase Ia/Ib study to evaluate the toxicity and immunologic response following administration of the recombinant vaccinia-CEA vaccine to patients with resected colorectal cancer who have no evidence of disease but are at high risk for disease recurrence.

这是一项IA/IB期研究，用于评估毒性和免疫学 进行重组疫苗疫苗后的响应 对于没有证据表明的切除结直肠癌的患者 疾病，但处于疾病复发的高风险。